more_reports

Rajeev Jashnani

UBS Securities

Recent Quotes

"JNJ's canagliflozin and Xarelto could add $2.5B in revenues by 2016."

— Rajeev Jashnani, UBS Securities (2/21/13)
more >



Due to permission requirements, not all quotes are shown.